Alpha Profiles · Company Profile

Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally.

https://registry.alpha.ac/companies/lineage-cell-therapeutics-inc

Entity: Public listing published
Primary listing: NYSE: LCTX
Verification: Partially verified
Last reviewed: 2026-09-18T04:46:27.635629+00:00

Overview

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for th

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

3 public records

Brian M. Culley

Chief Executive Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-191556Apr 29, 2026

George A. Samuel III

General Counsel and Corporate Secretary

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-191556Apr 29, 2026

Jill A. Howe

Chief Financial Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-191556Apr 29, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 18, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.